Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice

J J Naoum1, K J Woodside, S Zhang

  • 1Department of Surgery, Division of Vascular Surgery, University of Texas Medical Branch, Galveston, Texas 77555-0735, USA.

Insights

Rapamycin treatment increased endothelial nitric oxide synthase (eNOS) and altered matrix metalloproteinase (MMP) activity in Apo-E knockout mice, suggesting potential cardiovascular benefits. These changes in eNOS and MMPs may contribute to rapamycin

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Molecular Biology

Background:

  • Apolipoprotein E (Apo-E) knockout mice are a model for atherosclerosis.
  • Rapamycin (RPM) has antiproliferative effects and influences plasma lipids.
  • Endothelial nitric oxide synthase (eNOS) and matrix metalloproteinases (MMPs) play roles in vascular function.

Purpose of the Study:

  • To investigate the mechanisms of rapamycin's effects on eNOS and MMPs in Apo-E knockout mice.
  • To assess how rapamycin influences vascular health markers in a model of hyperlipidemia.

Main Methods:

  • Apo-E knockout mice were treated with rapamycin or placebo on a high-cholesterol diet.
  • Serum lipid profiles, aortic protein expression (eNOS, MMPs, TIMPs), and enzyme activity were analyzed.
  • Histology and immunohistochemistry were used for cellular localization.

Main Results:

  • Rapamycin increased eNOS and phosphorylated eNOS (p-eNOS) expression.
  • RPM treatment altered MMP-2 and MMP-9 activity and TIMP-2/TIMP-3 expression.
  • Akt and Caveolin-1 pathways were not significantly affected by rapamycin.

Conclusions:

  • Rapamycin modulates eNOS expression and MMP/TIMP balance in Apo-E knockout mice.
  • These vascular changes may contribute to the observed effects of rapamycin.
  • The mechanisms involve pathways beyond Akt and Caveolin-1 for eNOS regulation.